Puma Biotechnology (NASDAQ:PBYI) Announces Quarterly Earnings Results, Beats Estimates By $0.06 EPS

Key Points

• Puma Biotechnology reported quarterly EPS of $0.15, beating the $0.09 consensus estimate by $0.06, while revenue of $55.1 million fell short of analysts’ $57.5 million forecast.
• NERLYNX demand was mixed: U.S. demand increased 5% year over year, but new patient starts declined. Puma lowered its royalty forecast to $18–$19 million, citing a reduced China royalty rate.
• Puma raised its 2026 net-income outlook to $20–$22 million and ended the quarter with $108.5 million in cash and investments, with no debt.

Puma Biotechnology (NASDAQ:PBYI - Get Free Report) announced its quarterly earnings data on Thursday. The biopharmaceutical company reported $0.15 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.09 by $0.06, FiscalAI reports. Puma Biotechnology had a net margin of 11.50% and a return on equity of 20.76%. The firm had revenue of $55.10 million for the quarter, compared to analysts' expectations of $57.50 million.

Here are the key takeaways from Puma Biotechnology's conference call:

• Q3 revenue was $55.1 million, with net product revenue of $54.1 million, up from $53.6 million in Q2. However, U.S. NERLYNX net sales fell to $50.6 million from $53.6 million, while $3.6 million of product-supply revenue came from international partners.
• NERLYNX demand was mixed: U.S. demand rose 5% year over year but fell 3% quarter over quarter, while new patient starts declined 9% year over year and 13% sequentially. The company also lowered its 2026 product-revenue outlook slightly and cut its royalty forecast to $18–$19 million from $20–$23 million, citing a China royalty-rate reduction after generic market share crossed a threshold.
• Puma raised its full-year 2026 net-income outlook to $20–$22 million from $17–$20 million and expects $10–$12 million in Q4 net income. It ended Q3 with $108.5 million in cash, cash equivalents, and marketable securities and is now debt-free.
• Puma said preliminary ALISCA-Breast1 data supports considering a Phase III alisertib trial; updated interim results are expected at the San Antonio Breast Cancer Symposium in December, with discussions with regulators planned for the first half of 2027. The company also expects additional ALISCA-Lung1 interim data and initial ALISCA-Lung2 data in 2027, though these remain investigational programs.

Puma Biotechnology Stock Performance

NASDAQ:PBYI traded down $1.52 during trading hours on Friday, hitting $8.25. The stock had a trading volume of 1,279,729 shares, compared to its average volume of 359,117. Puma Biotechnology has a one year low of $4.57 and a one year high of $11.50. The company has a market cap of $425.87 million, a price-to-earnings ratio of 17.94 and a beta of 1.40. The business's 50 day moving average is $9.88 and its 200-day moving average is $7.99.

Insiders Place Their Bets

In related news, Director Troy Wilson sold 5,000 shares of the company's stock in a transaction on Monday, September 14th. The shares were sold at an average price of $9.10, for a total value of $45,500.00. Following the completion of the sale, the director owned 54,750 shares in the company, valued at $498,225. This represents a 8.37% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Alessandra Cesano sold 62,150 shares of the firm's stock in a transaction on Monday, September 14th. The stock was sold at an average price of $9.12, for a total value of $566,808.00. Following the sale, the director directly owned 56,700 shares in the company, valued at $517,104. The trade was a 52.29% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 22.20% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on PBYI shares. TD Cowen lifted their price objective on Puma Biotechnology from $5.00 to $6.00 and gave the stock a "hold" rating in a research note on Friday, August 7th. Weiss Ratings raised Puma Biotechnology from a "hold (c+)" rating to a "buy (b-)" rating in a research note on Thursday, October 8th. Finally, Wall Street Zen upgraded Puma Biotechnology from a "buy" rating to a "strong-buy" rating in a report on Saturday, August 15th. One analyst has rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $6.00.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc is a biopharmaceutical company focused on developing and commercializing medicines for the treatment of cancer. The company's lead product is NERLYNX (neratinib), an oral, irreversible tyrosine kinase inhibitor designed to target HER2 and other members of the epidermal growth factor receptor family.

NERLYNX is approved in the United States for the extended adjuvant treatment of adults with early-stage, HER2-positive breast cancer following adjuvant trastuzumab-based therapy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.